Telecommunication Services

SurgePays

SurgePays to Release FY2026 Q1 Earnings on May 15 Pre-Market EST, Forecast Revenue USD 15.5 M, EPS USD -0.19

SurgePays released FY2025 Q4 earnings on April 14 After-Market EST, actual revenue USD 0 (forecast USD 21.16 M), actual EPS USD 0 (forecast USD -0.16)

SurgePays released FY2025 Annual Earnings on April 14 After-Market (EST), actual revenue USD 56.96 M (forecast USD 61.94 M), actual EPS USD -1.7999 (forecast USD -1.275)

SurgePays to Release FY2025 Q4 Earnings on April 14 After-Market EST, Forecast Revenue USD 21.16 M, EPS USD -0.16

SurgePays released FY2025 Q3 earnings on November 12 After-Market EST, actual revenue USD 18.68 M (forecast USD 18.12 M), actual EPS USD -0.3799 (forecast USD -0.145)

SurgePays released FY2025 9 Months Earnings on November 12 After-Market EST, actual revenue USD 40.78 M, actual EPS USD -1.1204

SurgePays to Release FY2025 Q3 Earnings on November 12 After-Market EST, Forecast Revenue USD 18.12 M, EPS USD -0.145

SurgePays released FY2025 Semi-Annual earnings on August 13 After-Market EST, actual revenue USD 22.1 M, actual EPS USD -0.74

SurgePays released FY2025 Q2 earnings on August 13 After-Market EST, actual revenue USD 11.52 M (forecast USD 16.14 M), actual EPS USD -0.3599 (forecast USD -0.195)

SurgePays to Release FY2025 Q2 Earnings on August 13 After-Market (EST), Forecast Revenue USD 16.14 M, EPS USD -0.195

SurgePays Launches Prepaid Phone Service for Convenience Stores

Ascendiant Capital Maintains SurgePays Rating with Target Price Increase

SurgePays Inc. Changes Accounting Firms

Kevin Acquires SurgePays Common Stock

SurgePays Secures $7 Million in Financing for Business Expansion

SurgePays Sees Q1 Revenue Decline, Aims for $200M in April

SurgePays released FY2025 Q1 earnings on May 13 After-Market EST, actual revenue USD 10.58 M (forecast USD 9.763 M), actual EPS USD -0.3804 (forecast USD -0.355)

SurgePays Inc. Secures $7 Million in Funding for National Growth

Surgepays Inc Expected to Report a Loss of 23 Cents Per Share

SurgePays to Release 2025 Q1 Earnings

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

SURG

Surgepays (NASDAQ:SURG) reported a 51% year-over-year revenue growth to $16 million for Q1 2026, driven by a 71% increase in point of sale and prepaid services. The company surpassed 200,000 wireless subscribers and launched a Buy One Get One campaign to boost growth. Surgepays reduced customer acquisition costs significantly and added six new wholesale distribution partners, expecting a 30% increase in prepaid top-up volume. New monetization layers were introduced, contributing to incremental revenue, with continued growth anticipated through strategic partnerships.

benzinga_article

Surgepays Q1 2026 Earnings Call: Complete Transcript

SKLZ

On May 15, 2026, major companies including Diana Shipping, RBC Bearings, and Skillz are set to report earnings. TipRanks indicates expected earnings moves based on options prices, with significant implied moves for companies like SurgePays (+342.66%) and Sachem Capital (+135.24%). Investors are advised to research thoroughly before engaging in options trading.

Tip Ranks

Skillz

Diana Shipping

RBC Bearings

Sachem Capital

ARS Pharmaceuticals

DIANA SHIPPING INC C/WTS 14/12/2026 (TO PUR COM)

DIANA SHIPPING INC 8.875% PERP PFD SER B

Sachem Capital Pref Share SCCC 7.75 09/30/25

Sachem Capital Pref Share SCCE 6 03/30/27

Sachem Capital Pref Share SACC 6.875 12/30/24

Sachem Capital Pref Share SCCF 7.125 06/30/27

SACHEM CAPITAL CORP 7.75% SERIES A REDEEMABLE PREFERRED STCK

SACHEM CAPITAL CORP 8% NOTES DUE 30/09/2027 USD25.00

Sachem Capital Pref Share SCCD 6 12/30/26

Options Volatility and Implied Earnings Moves Today, May 15, 2026

Surgepays Q1 2026 Earnings Preview

businessinsider

Surgepays Q1 2026 Earnings Preview

NTLA

CTNT

SCNI

In the past hour, the overall market in the US stock market has shown significant differentiation, with technology stocks and the biopharmaceutical sector performing particularly well. The strong rise of Intellia Therapeutics has attracted market attention, driving the activity of related biotech stocks. Meanwhile, Cheetah Net Supply Chain and Scinai Immunotherapeutics have experienced significant declines, indicating a rapid shift of funds between different sectors. Short-term interest seems to be concentrated on those promising technology and pharmaceutical stocks, with large fluctuations and active market sentiment. The stock with the largest movement in the past hour, Intellia Therapeutics, surged by 31.33%, becoming the market focus. The strong performance of this stock has attracted a large influx of funds, boosting short-term sentiment and driving the overall rise of the biotech sector. Strong stocks include: 1. Organon: up 16.61%, with recent market attention on its product line and noticeable fund inflow. 2. MagnaChip Semiconductor: up 16.38%, benefiting from the recovery in semiconductor demand, with short-term funds actively participating. 3. SurgePays: up 7.70%, as the company's recent financial report exceeded expectations, attracting investor interest. 4. POET Tech: up 7.62%, with optimistic market expectations regarding its technological progress driving the stock price increase

- The U.S. stock market exhibited significant divergence, with notable performances in the technology and biotechnology sectors, particularly driven by Intellia Therapeutics, which rose by 31.33%.  
- Meanwhile, Cheetah Net Supply Chain and Scinai Immunotherapeutics faced declines of 20.00% and 19.17%, respectively, indicating rapid capital shifts among sectors.  
- Strong gains were also recorded in companies like Organon and MagnaChip Semiconductor, reflecting heightened investor interest in tech and healthcare stocks amid active market sentiment.

Price Alert

Intellia Therap

Cheetah Net Supply Chain

Scinai Immunotherapeutics

Organon

Magnachip Semiconduct

Zspace

Network 1 Tech

POET Tech

XORTX Therapeutics

Maxlinear

Faraday Future Intelligent Electric

Wing Yip Food China

Qualcomm

Wheeler Real Estate

U.S. Stock Market Movement Update: The biotechnology sector rebounded strongly, with Intellia rising 31.33% to lead the gains, while Cheetah fell 20%, attracting attention

In the past hour, the overall market in the U.S. stock market has shown significant differentiation, with technology stocks and the biopharmaceutical sector performing strongly, attracting a large influx of capital. In particular, the strong rise of Intellia Therap has seemingly ignited investor enthusiasm for biotechnology, driving the activity of related stocks. Meanwhile, Cheetah Net Supply Chain and Scinai Immunotherapeutics have encountered significant declines, reflecting a polarization of market sentiment. Short-term enthusiasm has notably increased in the technology and pharmaceutical sectors, with heightened volatility and a clear preference for high-growth stocks. The stock with the largest movement in the past hour, Intellia Therap, surged by 30.59%, becoming the market's focal point. The stock quickly rallied after the opening, attracting a large amount of short-term capital, with sentiment running high, seemingly indicating optimistic expectations for its future prospects. Strong stocks include: 1. Organon: up 16.52%, with recent market attention on its product line and noticeable capital inflow. 2. MagnaChip Semiconduct: up 14.67%, benefiting from a recovery in semiconductor demand, with short-term capital actively participating. 3. Hesai: up 8.46%, with ongoing innovations in the intelligent driving field sparking investor enthusiasm. 4. SurgePays: up 7.70%, with the company's new developments in payment solutions attracting market attention

- The U.S. stock market recently showed significant divergence, with technology and biotech sectors attracting substantial investment, particularly highlighted by a 30.59% surge in Intellia Therapeutics.  
- Strong performers included Organon, MagnaChip Semiconductor, and others, benefiting from renewed interest and demand in their respective areas.  
- Conversely, Cheetah Net Supply Chain and Scinai Immunotherapeutics faced considerable declines, reflecting polarized market sentiment amid concerns over supply chain management and R&D progress.

Hesai

System1

U.S. Stock Market Movement Update: Healthcare stocks rebound strongly, Intellia rises over 30%, Cheetah drops 20%

System1 rose 7.69% in the night session; SurgePays rose 7.30% in the night session; Intellia Therapeutics rose 27.81% in the night session; Organon rose 18.12% in the night session; Oncolytics Biotech rose 15.53% in the night session

U.S. stock night trading opens with fluctuations: System1 rises 7.69% in night trading; SurgePays rises 7.30% in night trading

Earnings Watch

SurgePays | 8-K: FY2025 Revenue: USD 56.96 M

SurgePays Inc (SURG) held its Q4 earnings call, highlighting operational progress amid liquidity risks. Despite a 6.4% decline in total revenue for 2025, management reported strong scalability and cost reductions, with G&A expenses down 26.9%. The Point-of-sale and Prepaid Services segment grew significantly, offsetting declines in subsidized revenue. However, year-end cash reserves were low at $1.7M, and working capital turned negative. The company remains reliant on external capital, raising $10.5M to support operations. Management emphasized ongoing transition risks following the expiration of key subsidies.

SurgePays Earnings Call Balances Growth With Liquidity Risk

SurgePays(SURG.US)

Surgepays Q1 2026 Earnings Call: Complete Transcript

Options Volatility and Implied Earnings Moves Today, May 15, 2026

Surgepays Q1 2026 Earnings Preview

U.S. Stock Market Movement Update: The biotechnology sector rebounded strongly, with Intellia rising 31.33% to lead the gains, while Cheetah fell 20%, attracting attention

U.S. Stock Market Movement Update: Healthcare stocks rebound strongly, Intellia rises over 30%, Cheetah drops 20%

U.S. stock night trading opens with fluctuations: System1 rises 7.69% in night trading; SurgePays rises 7.30% in night trading

SurgePays | 8-K: FY2025 Revenue: USD 56.96 M

SurgePays Earnings Call Balances Growth With Liquidity Risk